Navigation Links
New Year Quitters Urged to Invest in Their Family's Futures
Date:1/5/2009

LONDON, January 5 /PRNewswire/ --

- This is a reissue of a previously killed release from December 30th 2008. The source client has given permission to use the contents of this release.

Leading Child Trust Fund provider, The Children's Mutual (http://www.thechildrensmutual.co.uk) is encouraging all parents who decide to give up smoking as their New Year's resolution to consider putting the money that they will save towards their children's futures.

According to figures from the NHS, smokers dropping a five a day habit will save on average GBP40 a month. If this amount were in turn invested each month into a child's Child Trust Fund it could grow to GBP15,500 when the fund matures on the child's 18th birthday. The monthly saving raises to GBP158 for those quitting a 20 a day habit. This could fully fund a CTF with some left over each month.

While the NHS records numerous health benefits associated with giving up smoking, the potential to improve a child's future financial health can also be added to the list of reasons to quit.

Marketing Director of The Children's Mutual, Tony Anderson, comments; 'People often view the New Year as a time to take stock and we know that many use it as an opportunity to make promises to themselves and others - but these are not always easy to keep. What better incentive could there be for sticking to a resolution than the knowledge that, as well as improving your own long-term wellbeing, the commitment could further benefit your children as they enter adulthood in the years to come.'

    About The Children's Mutual - Home of The Child Trust Fund

    - The Children's Mutual's mission is to help parents,
      grandparents, family and friends fulfil their hopes for today's
      children.

    - The Children's Mutual is the only UK company that specialises

'/>"/>
SOURCE The Children's Mutual
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Urging New Year Quitters to Invest in Their Familys Futures
2. Lucky Quitters to Receive Big Money in Stop-Smoking Contest
3. New research shows that the smell of smoke does not trigger relapse in quitters
4. Quitters Honored at Wizards DC Tobacco Free Family Night
5. State Health Officials Seek Quitters as Part of Great American Smokeout
6. Caution Urged When Giving Kids Cold and Flu Meds
7. Independent Audit of Global Child Immunizations Urged
8. Caution Urged as Patients Seek Deals on Cosmetic Surgery
9. Even in Poor Economy, Consumers Urged to Prioritize Health Care
10. Lees Pharmaceutical Kept Up the Rapid Pace of Growth; Profit Attributable to Shareholders Surged 176% in the Nine Months of 2008
11. People with Diabetes Urged to Have Their Hearing Checked Regularly
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain 2For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain 3TaiGen Biotechnology Reports Phase I and Preclinical Data for TG-0054 at the 2009 American Society of Hematology (ASH) Annual Meeting 2New FDA Approved Breast Cancer Screening Tool 2New FDA Approved Breast Cancer Screening Tool 3KV Pharmaceutical Divests ANDA for Generic Version of Duac 28R 29 57754 1KV Pharmaceutical Divests ANDA for Generic Version of Duac 28R 29 57754 2KV Pharmaceutical Divests ANDA for Generic Version of Duac 28R 29 57754 3KV Pharmaceutical Divests ANDA for Generic Version of Duac 28R 29 57754 4KV Pharmaceutical Divests ANDA for Generic Version of Duac 28R 29 57754 5KV Pharmaceutical Divests ANDA for Generic Version of Duac 28R 29 57754 6Merrimack Pharmaceuticals Names Clet Niyikiza Ph D Senior Vice President Development 14175 1Merrimack Pharmaceuticals Names Clet Niyikiza Ph D Senior Vice President Development 14175 2Alzheimers Soars Global Focus Needed 3A Study 57748 1Alzheimers Soars Global Focus Needed 3A Study 57748 2Alzheimers Soars Global Focus Needed 3A Study 57748 3
Other Medicine Technology:Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 2Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 3Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 4Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 5Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 6Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 2Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 3Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 4Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 5Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 6Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 7Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 8Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 9Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 10